-
Sanofi Expands Insulin Savings Program To Cover All US Patients
Friday, September 26, 2025 - 1:40pm | 565Read More...The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA’s (NASDAQ: SNY) Genzyme Corporation. SNY is demonstrating bullish strength. Check out the latest moves...
-
Jefferies Downgrades Genzyme To Hold, PT At $80
Thursday, February 17, 2011 - 8:19am | 24Read More...Jefferies & Company has downgraded Genzyme (NASDAQ: GENZ) from Buy to Hold and maintains its $80 price target.
-
Hapoalim Securities Expects Genzyme To Hold Out For A Higher Offer
Monday, October 25, 2010 - 7:54am | 124Read More...Genzyme Corporation (NASDAQ: GENZ) used its Analyst Day to outline why it thinks the Sanofi bid is too low, but stated that it was not against a sale at an appropriate price, Hapoalim Securities reports. “We would expect Genzyme to hold out for a higher offer and due to the limited opportunities...
-
Genzyme Hosting Investor Luncheon Friday In New York
Thursday, October 21, 2010 - 7:28am | 141Read More...Piper Jaffray has published a research report on Genzyme Corporation (NASDAQ: GENZ) following 3Q earnings results that came in below consensus estimates while still exceeding expectations for sales. In the report, Piper Jaffray writes "Genzyme reported 3Q earnings below consensus but Cerezyme sales...
-
Icahn Wants Four Seats On Genzyme (GENZ) Board
Monday, February 22, 2010 - 11:14am | 86Read More...Billionaire investor Carl Icahn informed troubled biotechnology company Genzyme Corporation (Nasdaq: GENZ) that he intends to nominate himself and three other to four of the company's nine board of directors. Genzyme Corporation has been under pressure because of drug shortages caused by the...
